Skip to main content

64304500CRD2001 A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn’s Disease

NCT02877134

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn’s Disease

Associated Conditions

Colon

Principal Investigator

Sponsor

Janssen Research & Development

The experimental drugs used in this study are called JNJ 64304500 and ustekinumab. The purpose of this study is to see if if JNJ 64304500 is useful for treating patients with moderately to severely active Crohn’s Disease. The ustekinumab treatment has been included in this study in order to understand patient responses to Crohn’s diseases treatments using a drug whose responses have been previously tested. The effects of ustekinumab will be compared to placebo and not directly to JNJ-64304500. Not everyone in the study will get JNJ 64304500 or ustekinumab. You will either receive JNJ 64304500, ustekinumab or placebo (dummy treatment).